相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
Hagop M. Kantarjian et al.
LEUKEMIA (2021)
Impact of frontline treatment approach on outcomes of myeloid blast phase CML
Kapil Saxena et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
Abhishek Maiti et al.
ACTA HAEMATOLOGICA (2020)
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia
Yasmin Abaza et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party
Aleksandar Radujkovic et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Management of Chronic Myeloid Leukemia in Advanced Phase
Massimiliano Bonifacio et al.
FRONTIERS IN ONCOLOGY (2019)
Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia
Mathilde Ruggiu et al.
LEUKEMIA & LYMPHOMA (2018)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes et al.
BLOOD (2018)
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
Susan Branford et al.
BLOOD (2018)
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
Marilyn M. Li et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making
Christina Yap et al.
CLINICAL CANCER RESEARCH (2017)
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia
Rita Assi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Prognostic Factors and Survival Outcomes in Patients With Chronic Myeloid Leukemia in Blast Phase in the Tyrosine Kinase Inhibitor Era: Cohort Study of 477 Patients
Preetesh Jain et al.
CANCER (2017)
Implementing the EffTox dose-finding design in the Matchpoint trial
Kristian Brock et al.
BMC MEDICAL RESEARCH METHODOLOGY (2017)
Management of CML-blast crisis
Ruediger Hehlmann et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
Elias Jabbour et al.
LANCET ONCOLOGY (2015)
HCVAD Plus Imatinib or Dasatinib in Lymphoid Blastic Phase Chronic Myeloid Leukemia
Paolo Strati et al.
CANCER (2014)
Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials With Delayed Outcomes
Ick Hoon Jin et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2014)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis
H. J. Khoury et al.
BONE MARROW TRANSPLANTATION (2012)
Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation
Dragana Milojkovic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
Susanne Saussele et al.
BLOOD (2010)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis
Stefan Fruehauf et al.
CANCER (2007)
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase
Alfonso Quintas-Cardama et al.
LEUKEMIA & LYMPHOMA (2007)
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia
Simona Soverini et al.
CLINICAL CANCER RESEARCH (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients:: a retrospective analysis from the French intergroup of CML (Fi(φ)-LMC GROUP)
F. E. Nicolini et al.
LEUKEMIA (2006)
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia
D Rea et al.
LEUKEMIA (2006)
Dose-finding based on efficacy-toxicity trade-offs
PF Thall et al.
BIOMETRICS (2004)
分享论文
